-
公开(公告)号：US20110086074A1
公开(公告)日：2011-04-14
申请号：US12995711
申请日：2009-06-02
申请人： Pradeep Jairao Karatgi , Thilek Kumar Muniyappan , Shantanu Yeshwant Damle , Sesha Sai Marella , Harshal Prabhakar Bhagwatwar , Raviraj Sukumar Pillai , Ish Kumar Khanna
发明人： Pradeep Jairao Karatgi , Thilek Kumar Muniyappan , Shantanu Yeshwant Damle , Sesha Sai Marella , Harshal Prabhakar Bhagwatwar , Raviraj Sukumar Pillai , Ish Kumar Khanna
IPC分类号： A61K31/549 , A61K9/00 , A61P29/00 , A61P3/06 , A61P3/10
CPC分类号： A61K31/455 , A61K9/2081 , A61K9/209 , A61K9/2886 , A61K9/5026 , A61K9/5073 , A61K9/5084 , A61K31/54 , A61K45/06 , A61K2300/00
摘要： Pharmaceutical formulations comprising a combination of niacin and an oxicam NSAID, for oral administration, and methods of preparing the formulations.
摘要翻译： 包含烟酸和奥昔康NSAID的组合用于口服给药的药物制剂和制备该制剂的方法。
-
公开(公告)号：US20120064161A1
公开(公告)日：2012-03-15
申请号：US13299591
申请日：2011-11-18
申请人： Rajesh Vooturi , Dhananjay Singare , Shantanu Yeshwant Damle , Pradeep Jairao Karatgi , Sesha Sai Marella , Harshal Prabhakar Bhagwatwar , Ish Kumar Khanna , Raviraj Sukumar Pillai , Sivaram Pillarisetti
发明人： Rajesh Vooturi , Dhananjay Singare , Shantanu Yeshwant Damle , Pradeep Jairao Karatgi , Sesha Sai Marella , Harshal Prabhakar Bhagwatwar , Ish Kumar Khanna , Raviraj Sukumar Pillai , Sivaram Pillarisetti
IPC分类号： A61K9/28 , A61P9/12 , A61K9/32 , A61K31/455 , A61K9/36
CPC分类号： A61K31/455 , A61K9/209 , A61K9/2846 , A61K9/2866 , A61K9/2886 , A61K45/06 , A61K2300/00
摘要： Pharmaceutical formulations comprising niacin in a matrix comprising a hydrophobic polymer that modifies release of niacin.
摘要翻译： 包含烟酸在包含改性烟酸释放的疏水性聚合物的基质中的药物制剂。
-
公开(公告)号：US20110123575A1
公开(公告)日：2011-05-26
申请号：US12995718
申请日：2009-06-02
申请人： Rajesh Vooturi , Dhanajay Singare , Shantanu Yeshwant Damle , Pradeep Jairao Karatgi , Sesha Sai Marella , Harshal Prabhakar Bhagwatwar , Ish Kumar Khanna , Raviraj Sukumar Pillai
发明人： Rajesh Vooturi , Dhanajay Singare , Shantanu Yeshwant Damle , Pradeep Jairao Karatgi , Sesha Sai Marella , Harshal Prabhakar Bhagwatwar , Ish Kumar Khanna , Raviraj Sukumar Pillai
IPC分类号： A61K9/00 , A61K31/4406 , A61P3/06 , A61P9/10
CPC分类号： A61K31/455 , A61K9/5031 , A61K9/5047 , A61K9/5073
摘要： Modified release pharmaceutical formulations comprising niacin in a non-swellable core, and processes for preparation of the formulations.
摘要翻译： 包含非可溶胀核心中的烟酸的改性释放药物制剂以及制剂的制备方法。
-
公开(公告)号：US06949578B2
公开(公告)日：2005-09-27
申请号：US10891361
申请日：2004-07-14
申请人： Ish Kumar Khanna , Michael Clare , Alan F. Gasiecki , Thomas Rogers , Barbara Chen , Mark Russell , Hwang-Fun Lu
发明人： Ish Kumar Khanna , Michael Clare , Alan F. Gasiecki , Thomas Rogers , Barbara Chen , Mark Russell , Hwang-Fun Lu
IPC分类号： A61K31/4168 , A61K31/4375 , A61K31/44 , A61K31/4402 , A61K31/443 , A61K31/4439 , A61K31/444 , A61K31/5383 , A61P3/14 , A61P9/00 , A61P9/10 , A61P19/02 , A61P19/10 , A61P21/00 , A61P27/02 , A61P35/00 , A61P35/04 , C07D213/74 , C07D231/38 , C07D233/88 , C07D405/12 , C07D413/12 , C07D417/12 , C07D471/04 , C07D498/04 , A61K31/415 , A61K31/4172 , C07D233/38
CPC分类号： C07D213/74 , C07D231/38 , C07D233/88 , C07D405/12 , C07D413/12 , C07D417/12 , C07D471/04
摘要： The present invention relates to a class of compounds represented by the Formula I or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the αvβ3 and/or αvβ5 integrin.
摘要翻译： 本发明涉及一类由式I表示的化合物或其药学上可接受的盐，包含式I化合物的药物组合物和选择性抑制或拮抗α > 3和/或α
-
5.发明授权公开(公告)号：US06921767B2
公开(公告)日：2005-07-26
申请号：US10326299
申请日：2002-12-20
申请人： Nagarajan R. Srinivasan , Ish Kumar Khanna , Michael Clare , Alan Gasiecki , Thomas Rogers , Barbara Chen , Mark Russell , Hwang-Fun Lu , Yu Yi , Renee M. Huff , Bipinchandra N. Desai , Balekudru Devadas , Mihir D. Parikh , Thomas Penning
发明人： Nagarajan R. Srinivasan , Ish Kumar Khanna , Michael Clare , Alan Gasiecki , Thomas Rogers , Barbara Chen , Mark Russell , Hwang-Fun Lu , Yu Yi , Renee M. Huff , Bipinchandra N. Desai , Balekudru Devadas , Mihir D. Parikh , Thomas Penning
IPC分类号： C07D213/74 , C07D231/38 , C07D233/88 , C07D405/12 , C07D413/12 , C07D417/12 , C07D471/04 , C07D498/04 , C07D239/14 , A61K31/505 , A61P9/10 , A61P19/10
CPC分类号： C07D213/74 , C07D231/38 , C07D233/88 , C07D405/12 , C07D413/12 , C07D417/12 , C07D471/04
摘要： The present invention relates to a class of compounds represented by the Formula I or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the αvβ3 and/or αvβ5 integrin.
摘要翻译： 本发明涉及一类由式I表示的化合物或其药学上可接受的盐，包含式I化合物的药物组合物和选择性抑制或拮抗α > 3和/或α
-
公开(公告)号：US06720315B2
公开(公告)日：2004-04-13
申请号：US09882137
申请日：2001-06-15
申请人： Thomas Rogers , Michael Clare , Hwang-Fun Lu , Mark Russell , James W. Malecha , Ish Kumar Khanna , Thomas Penning , Srinivasan Raj Nagarajan , Heather Stenmark
发明人： Thomas Rogers , Michael Clare , Hwang-Fun Lu , Mark Russell , James W. Malecha , Ish Kumar Khanna , Thomas Penning , Srinivasan Raj Nagarajan , Heather Stenmark
IPC分类号： A61K3133
CPC分类号： C07D213/74 , C07D239/14 , C07D401/12
摘要： The present invention relates to a class of compounds represented by the Formula 1. or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula 1, and methods of selectively inhibiting or antagonizing the &agr;V&bgr;3 and/or the &agr;V&bgr;5 integrin.
摘要翻译： 本发明涉及一类由式1表示的化合物或其药学上可接受的盐，包含式1化合物的药物组合物和选择性抑制或拮抗αVβ3和/或αVbeta5整联蛋白的方法。
-
公开(公告)号：US5852210A
公开(公告)日：1998-12-22
申请号：US825080
申请日：1997-03-27
申请人： Barbara B. Chen , Helen Y. Chen , Michael Clare , Stephen H. Docter , Ish Kumar Khanna , Francis Jan Koszyk , James W. Malecha , Julie Marion Miyashiro , Thomas D. Penning , Joseph G. Rico , Peter G. Ruminski , Mark A. Russell , Richard Mathias Weier , Xiangdong Xu , Stella S. Yu , Yi Yu
发明人： Barbara B. Chen , Helen Y. Chen , Michael Clare , Stephen H. Docter , Ish Kumar Khanna , Francis Jan Koszyk , James W. Malecha , Julie Marion Miyashiro , Thomas D. Penning , Joseph G. Rico , Peter G. Ruminski , Mark A. Russell , Richard Mathias Weier , Xiangdong Xu , Stella S. Yu , Yi Yu
IPC分类号： A61K31/00 , A61K31/195 , A61K31/215 , A61K31/216 , A61K31/275 , A61K31/277 , A61K31/415 , A61K31/4164 , A61K31/4178 , A61K31/42 , A61K31/421 , A61K31/47 , A61K31/4709 , A61K31/495 , A61K31/496 , A61K31/4965 , A61K31/497 , A61K31/505 , A61K31/506 , A61K31/54 , A61P3/00 , A61P3/14 , A61P9/00 , A61P9/14 , A61P19/00 , A61P19/10 , A61P35/00 , A61P35/04 , C07C205/34 , C07C205/35 , C07C205/37 , C07C205/44 , C07C205/45 , C07C205/56 , C07C205/57 , C07C275/42 , C07C279/18 , C07C279/22 , C07C279/24 , C07D231/06 , C07D233/50 , C07D233/54 , C07D233/64 , C07D239/14 , C07D239/42 , C07D263/32 , C07D279/06 , C07D401/12 , C07D403/12 , C07C241/00 , C07C205/00 , C07D233/44 , C07D239/02
CPC分类号： C07D231/06 , C07C205/34 , C07C205/35 , C07C205/37 , C07C205/44 , C07C205/45 , C07C205/56 , C07C205/57 , C07C275/42 , C07C279/18 , C07C279/22 , C07C279/24 , C07D233/50 , C07D233/64 , C07D239/14 , C07D239/42 , C07D263/32 , C07D279/06 , C07D401/12 , C07D403/12
摘要： The present invention relates to a class of compounds represented by the Formula I ##STR1## or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the .alpha..sub.v .beta..sub.3 integrin.
摘要翻译： 本发明涉及一类由式I表示的化合物或其药学上可接受的盐，包含式I化合物的药物组合物和选择性抑制或拮抗αvβ3整联蛋白的方法。
-
8.发明授权Heteroaralkyl and heteroarylthioalkyl thiophenolic compounds as inhibitors of 5-lipoxygenase 失效杂芳基烷基和杂芳硫基烷基硫代酚化合物作为5-脂氧合酶的抑制剂
公开(公告)号：US5688822A
公开(公告)日：1997-11-18
申请号：US597778
申请日：1996-02-07
IPC分类号： C07D209/08 , C07D215/22 , C07D215/227 , C07D235/06 , C07D263/58 , C07D471/04 , A61K31/40 , A61K31/415 , A61K31/42 , C07D235/22
CPC分类号： C07D215/227 , C07D209/08 , C07D235/06 , C07D263/58 , C07D471/04
摘要： Compounds of the formula: ##STR1## Formula I and the pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising a therapeutically-effective amount of the compounds or salts in combination with a pharmaceutically-acceptable carrier and methods for treating 5-lipoxygenase mediated conditions, inflammation-associated disorders and allergies.
摘要翻译： 式I化合物及其药学上可接受的盐，包含治疗有效量的化合物或其盐与药学上可接受的载体组合的药物组合物和治疗5-脂氧合酶介导的病症的方法， 相关疾病和过敏。
-
公开(公告)号：US5652363A
公开(公告)日：1997-07-29
申请号：US725285
申请日：1996-10-02
IPC分类号： C07D498/04 , C07D265/36
CPC分类号： C07D498/04
摘要： The present invention relates to compounds of the formula ##STR1## and pharmaceutical compositions containing a therapeutically effective amount of the compounds in combination with a pharmaceutically acceptable carrier and a method for treating diseases mediated by platelet activating factor.
摘要翻译： 本发明涉及式IMA的化合物和含有治疗有效量的化合物与药学上可接受的载体的组合的药物组合物和用于治疗由血小板活化因子介导的疾病的方法。
-
公开(公告)号：US20130303525A1
公开(公告)日：2013-11-14
申请号：US13811020
申请日：2011-07-19
申请人： Pradip Kumar Sasmal , Vamsee Krishna Chintakunta , Vijay Potluri , Ish Kumar Khanna , Ashok Tehim , Mahaboobi Jaleel , Thomas Hogberg , Oystein Rist , Lisbeth Elster , Thomas Michael Frimurer , Lars-Ole Gerlach
发明人： Pradip Kumar Sasmal , Vamsee Krishna Chintakunta , Vijay Potluri , Ish Kumar Khanna , Ashok Tehim , Mahaboobi Jaleel , Thomas Hogberg , Oystein Rist , Lisbeth Elster , Thomas Michael Frimurer , Lars-Ole Gerlach
IPC分类号： C07D419/12 , C07D401/12 , C07D413/14 , C07D403/12 , C07D207/09 , C07D417/12 , C07D413/12
CPC分类号： C07D419/12 , C07D207/09 , C07D207/12 , C07D209/34 , C07D213/76 , C07D215/12 , C07D215/227 , C07D231/56 , C07D249/18 , C07D261/20 , C07D263/56 , C07D263/58 , C07D275/06 , C07D277/30 , C07D279/02 , C07D295/13 , C07D401/12 , C07D403/12 , C07D413/12 , C07D413/14 , C07D417/12
摘要： The present invention relates to a series of substituted compounds having the general formula (I), including their stereoisomers and/or their pharmaceutically acceptable salts. (I) Wherein A, m, R1s, R2, R3, R4 are as defined herein. This invention also relates to methods of making these compounds including intermediates. The compounds of this invention are effective at the kappa (κ) opioid receptor (KOR) site. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic pain, and associated disorders, particularly functioning peripherally at the CNS.
摘要翻译： 本发明涉及一系列具有通式（I）的取代的化合物，包括其立体异构体和/或其药学上可接受的盐。 （I）其中A，m，R 1，R 2，R 3，R 4如本文所定义。 本发明还涉及制备这些化合物包括中间体的方法。 本发明的化合物在κ（κ）阿片样物质受体（KOR）位点是有效的。 因此，本发明的化合物可用作药物，特别是用于治疗和/或预防各种中枢神经系统疾病（CNS），包括但不限于急性和慢性疼痛以及相关疾病，特别是周边功能 在CNS。
-
-
-
-
-
-
-
-
-
搜索结果
22 条记录 (耗时 0.039 秒)
